Why the study?
Does telmisartan normalize plasma cortisol levels in patients with coronary artery disease, anemia, and type 2 diabetes?
Does telmisartan normalize plasma cortisol levels in patients with coronary artery disease, anemia, and type 2 diabetes?
Answers are grounded in this paper and cite their sources.
Adding telmisartan to standard therapy may normalize plasma cortisol levels in patients with CAD, anemia, and type 2 diabetes, suggesting a reduction in stress-system tension.
The peculiarities of glucocorticoid adrenal function in patients with coronary artery disease complicated by concomitant anemia and diabetes mellitus type 2 are discussed in the article. It was established that the level of plasma cortisol depended on the concomitant anemic syndrome severity. The inclusion of telmisartan to the scheme of complex treatment of the patients resulted in normalization of plasma cortisol level, which proved the reduction of stress-limited systems tension on the background of the proposed treatment regimen.
No takes yet. Share an insight, caveat, or question.
Pavliukovych et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: